The body’s immune system runs on a circadian rhythm, meaning the timing of treatments like immunotherapy or vaccines can influence how well they work. Studies in humans and animals show that morning administration often leads to stronger immune responses and better survival outcomes, a finding now being explored for canine cancer care.

Learn more about Elias Cancer Immunotherapy (ECI), a newly USDA-approved treatment for dogs with osteosarcoma. It explains how ECI works, its benefits, success rates, costs, and availability for families seeking new options in canine cancer care.

A new clinical trial led by UC Davis School of Veterinary Medicine is investigating a novel immunotherapy designed to help the immune system recognize and attack cancer cells. If proven effective, this treatment has the potential to extend survival and improve outcomes for dogs with metastatic cancer.